癌症干细胞市场：按癌症类型、产品类型、干细胞来源、作用机制、应用、最终用户和地区划分

据估计，癌症干细胞市场在 2025 年的价值为 33.4 亿美元，预计到 2032 年将达到 63.9 亿美元，2025 年至 2032 年的复合年增长率为 9.7%。

癌症干细胞（CSCs）是肿瘤内一种独特的细胞群，具有自我更新和分化成多种细胞谱系的能力，是肿瘤学研究和开发的重要标靶。它们能够启动肿瘤发生、促进转移并导致治疗抗药性，因此在精准癌症医学领域占据核心地位。

全球癌症干细胞市场涵盖了一系列研究工具、治疗方法和诊断解决方案，旨在识别、分离和标靶化这些难以捉摸的细胞群。该市场涉及多种癌症类型，包括乳癌、肺癌、大肠癌、脑肿瘤和骨髓恶性肿瘤，其应用范围广泛，涵盖药物研发、生物标记鑑定和个人化治疗策略。对癌症干细胞生物学的深入了解正在推动对流式细胞技术系统、细胞培养基、抗体和小分子抑制剂等专用技术的重大投资。

市场动态

全球癌症干细胞市场受多种关键市场驱动因素的推动，这些因素正在加速其扩张和技术进步。其中最主要的成长要素是全球癌症负担的指数级增长。每年新增癌症病例超过1900万例，因此迫切需要创新的治疗方法来应对治疗抗药性和肿瘤復发问题。

政府机构、製药公司和生物技术公司对癌症研究的大量投资显着提高了癌症干细胞（CSC）相关研究的资金筹措可能性。同时，在干细胞生物学和癌症发病机制领域的突破性发现为药物研发和个人化医疗开闢了新的途径。单细胞定序、CRISPR基因编辑和先进的细胞分选系统等先进技术平台彻底改变了我们研究CSC的能力，使我们能够更精确地识别和表征这些细胞群。

然而，市场成长存在许多限制因素：专业实验室设备和试剂的高成本限制了小规模研究机构和发展中地区的获取；癌症干细胞的稀有性和表型可塑性给研究人员带来了重大障碍，因为分离和表征癌症干细胞存在技术挑战；针对癌症标靶治疗的严格监管要求导致研发週期长、成本高。

儘管面临这些挑战，市场仍蕴藏着巨大的机会，包括：开髮用于早期癌症检测和监测的液态生物检体新应用；拓展对癌症干细胞发挥关键作用的罕见癌症类型的研究；以及日益普及的3D细胞培养和类器官技术，这些技术能够更真实地模拟体内肿瘤微环境。未来几年，针对癌细胞和癌症干细胞群的联合治疗日益受到重视，加上生物标记发现计画投入的不断增加，预计将推动市场持续成长和创新。

本报告的主要特点

• 本报告对全球癌症干细胞市场进行了详细分析，并给出了预测期（2025-2032 年）的市场规模和复合年增长率，以 2024 年为基准年。
• 它还重点介绍了各个细分市场的潜在商机，并描述了该市场中一系列有吸引力的投资提案。
• 它还提供了有关市场驱动因素、限制因素和机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的关键见解。
• 全球癌症干细胞市场的主要企业将根据以下参数进行分析，例如公司概况、产品系列、主要亮点、财务表现和策略。
• 本报告提供的见解将使负责人和企业经营团队能够就未来的产品发布、合作关係、市场扩张和行销策略做出明智的决策。
• 《全球癌症干细胞市场》报告面向该行业的各类相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员可以透过用于分析全球癌症干细胞市场的各种策略矩阵更轻鬆地做出决策。

目录

第一章 分析目标与先决条件

• 分析目的
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要

第三章：市场动态、监管与趋势分析

• 市场动态
• 司机
• 抑制因素
• 机会
• 影响分析
• 重大进展
• 监管情景
• 产品发布/核准
• PEST分析
• 波特五力分析
• 企业合併情景
• 产业趋势

第四章 全球癌症干细胞市场（依癌症类型划分）（2020-2032 年）

• 乳癌
• 血癌
• 肺癌
• 脑肿瘤
• 大肠直肠癌
• 胰臟癌
• 膀胱癌
• 肝癌
• 其他类型的癌症

第五章 全球癌症干细胞市场（依产品类型划分）（2020-2032 年）

• 细胞培养产品
• 细胞分离产品
• 细胞分析产品
• 分子分析产品
• 其他辅助工具/试剂（例如，培养基、标记物、检测试剂盒）

6. 全球癌症干细胞市场（依干细胞来源划分）（2020-2032 年）

• 骨髓来源
• 週边血来源
• 脐带血来源
• 诱导性多功能干细胞（iPS细胞）

7. 全球癌症干细胞市场依作用机制划分（2020-2032 年）

• 标靶癌症干细胞疗法
• 基于免疫疗法的方法
• 其他（化疗抗药性逆转剂）

第八章 全球癌症干细胞市场按应用领域划分（2020-2032 年）

• 研究与开发
• 生物标记鑑定
• 药物发现与筛检
• 肿瘤发生研究
• 诊断用途
• 癌症预后
• 微量残存疾病的检测
• 治疗应用
• 临床治疗
• 辅助性治疗

9. 全球癌症干细胞市场（按最终用户划分）（2020-2032 年）

• 医院、癌症治疗中心
• 製药和生物技术公司
• 学术和研究机构/研究机构
• 委外研发机构（CRO）
• 其他终端使用者（细胞库、诊断中心）

第十章 全球癌症干细胞市场（按地区划分）（2020-2032 年）

• 北美洲
  • 美国
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲国家
• 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 其他亚太地区
• 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东国家
• 非洲
  • 南非
  • 北非
  • 中非

第十一章 竞争格局

• Lineage Cell Therapeutics, Inc.
• FUJIFILM Irvine Scientific
• Thermo Fisher Scientific Inc.
• Merck KGaA
• MacroGenics, Inc.
• Miltenyi Biotec
• AbbVie Inc.
• STEMCELL Technologies Inc.
• Bionomics
• Sino Biological Inc.
• Celgene Corporation
• Incyte Corporation
• Novartis AG
• Pfizer Inc.
• Lonza Group AG

第十二章 分析师建议

• 机会
• 分析师观点
• Coherent Opportunity Map (COM)

第十三章 参考文献与分析方法

• 参考
• 分析方法
• 关于 Coherent Market Insights

Cancer Stem Cells Market is estimated to be valued at USD 3.34 Bn in 2025 and is expected to reach USD 6.39 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.7% from 2025 to 2032.

Cancer stem cells (CSCs) represent a unique subpopulation of cells within tumors that possess self-renewal capabilities and multilineage differentiation potential, making them critical targets in oncology research and therapeutic development. These cells are characterized by their ability to initiate tumor formation, drive metastasis, and contribute to treatment resistance, positioning them at the forefront of precision cancer medicine.

The global cancer stem cells market encompasses a comprehensive ecosystem of research tools, therapeutic agents, and diagnostic solutions designed to identify, isolate, and target these elusive cellular populations. This market spans various cancer types including breast, lung, colorectal, brain, and hematological malignancies, with applications extending across drug discovery, biomarker identification, and personalized treatment strategies. The increasing understanding of CSC biology has catalyzed significant investments in specialized technologies such as flow cytometry systems, cell culture media, antibodies, and small molecule inhibitors.

Market Dynamics

The global cancer stem cells market is propelled by several key drivers that collectively accelerate its expansion and technological advancement. The primary growth catalyst stems from the exponentially increasing global cancer burden, with over 19 million new cases diagnosed annually, creating urgent demand for innovative therapeutic approaches that address treatment resistance and tumor recurrence.

Substantial investments in cancer research by government agencies, pharmaceutical companies, and biotechnology firms have significantly enhanced funding availability for CSC-related studies, while breakthrough discoveries in stem cell biology and cancer pathogenesis have opened new avenues for drug development and personalized medicine approaches. Advanced technological platforms including single-cell sequencing, CRISPR gene editing, and sophisticated cell sorting systems have revolutionized CSC research capabilities, enabling more precise identification and characterization of these cellular populations.

However, market growth faces notable restraints including the high costs associated with specialized research equipment and reagents, which can limit accessibility for smaller research institutions and developing regions. Technical challenges in CSC isolation and characterization due to their rarity and phenotypic plasticity create significant barriers for researchers, while stringent regulatory requirements for CSC-targeting therapeutics extend development timelines and increase costs.

Despite these challenges, the market presents substantial opportunities through emerging applications in liquid biopsy development for early cancer detection and monitoring, expanding research into rare cancer types where CSCs play critical roles, and growing adoption of 3D cell culture and organoid technologies that better recapitulate in vivo tumor environments. The increasing focus on combination therapies targeting both bulk tumor cells and cancer stem cell populations, coupled with rising investments in biomarker discovery programs, positions the market for sustained growth and innovation in the coming years.

Key Features of the Study

• This report provides in-depth analysis of the global cancer stem cells market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global cancer stem cells market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Lineage Cell Therapeutics, Inc., FUJIFILM Irvine Scientific, Thermo Fisher Scientific Inc., Merck KGaA, MacroGenics, Inc., Miltenyi Biotec, AbbVie Inc., STEMCELL Technologies Inc., Bionomics, Sino Biological Inc., Celgene Corporation, Incyte Corporation, Novartis AG, Pfizer Inc., and Lonza Group AG
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global cancer stem cells market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer stem cells market

Market Segmentation

• Cancer Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Breast Cancer
  • Blood Cancer
  • Lung Cancer
  • Brain Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Bladder Cancer
  • Liver Cancer
  • Other Cancer Types
• Product Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Cell culturing products
  • Cell separation products
  • Cell analysis products
  • Molecular analysis products
  • Other supporting tools/reagents (e.g. media, markers, assay kits)
• Stem-cell Source Insights (Revenue, USD Bn, 2020 - 2032)
  • Bone Marrow-derived
  • Peripheral Blood-derived
  • Umbilical Cord Blood-derived
  • Induced Pluripotent Stem Cells (iPSCs)
• Mode of Action Insights (Revenue, USD Bn, 2020 - 2032)
  • Targeted Cancer Stem Cell Therapies
  • Immunotherapy-based Approaches
  • Others (Chemotherapy Resistance Reversal Agents)
• Application Insights (Revenue, USD Bn, 2020 - 2032)
  • Research and Development
  • Biomarker Identification
  • Drug Discovery and Screening
  • Tumorigenesis Studies
  • Diagnostic Applications
  • Cancer Prognosis
  • Minimal Residual Disease Detection
  • Therapeutic Applications
  • Clinical Treatment
  • Adjunct Therapy
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals and cancer treatment centers
  • Pharmaceutical and biotechnology companies
  • Academic and research institutes/laboratories
  • Contract research organizations (CROs)
  • Other end users (Cell banks, diagnostic centers)
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Lineage Cell Therapeutics, Inc.
  • FUJIFILM Irvine Scientific
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • MacroGenics, Inc.
  • Miltenyi Biotec
  • AbbVie Inc.
  • STEMCELL Technologies Inc.
  • Bionomics
  • Sino Biological Inc.
  • Celgene Corporation
  • Incyte Corporation
  • Novartis AG
  • Pfizer Inc.
  • Lonza Group AG

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Cancer Stem Cells Market, By Cancer Type
  • Global Cancer Stem Cells Market, By Product Type
  • Global Cancer Stem Cells Market, By Stem Cell Source
  • Global Cancer Stem Cells Market, By Mode of Action
  • Global Cancer Stem Cells Market, By Application
  • Global Cancer Stem Cells Market, By End User
  • Global Cancer Stem Cells Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Cancer Stem Cells Market, By Cancer Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Breast Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Blood Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Lung Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Brain Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Colorectal Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Pancreatic Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Bladder Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Liver Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Other Cancer Types
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Cancer Stem Cells Market, By Product Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Cell culturing products
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Cell separation products
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Cell analysis products
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Molecular analysis products
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Other supporting tools/reagents (e.g. media, markers, assay kits)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Cancer Stem Cells Market, By Stem Cell Source, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Bone Marrow-derived
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Peripheral Blood-derived
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Umbilical Cord Blood-derived
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Induced Pluripotent Stem Cells (iPSCs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Cancer Stem Cells Market, By Mode of Action, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Targeted Cancer Stem Cell Therapies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Immunotherapy-based Approaches
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others (Chemotherapy Resistance Reversal Agents)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Cancer Stem Cells Market, By Application, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Research and Development
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Biomarker Identification
• Drug Discovery and Screening
• Tumorigenesis Studies
• Diagnostic Applications
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Cancer Prognosis
• Minimal Residual Disease Detection
• Therapeutic Applications
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Clinical Treatment
• Adjunct Therapy

9. Global Cancer Stem Cells Market, By End User, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospitals and cancer treatment centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Pharmaceutical and biotechnology companies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Academic and research institutes/laboratories
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Contract research organizations (CROs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Other end users (Cell banks, diagnostic centers)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Cancer Stem Cells Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Stem Cell Source, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Mode of Action, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Stem Cell Source, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Mode of Action, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Stem Cell Source, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Mode of Action, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Stem Cell Source, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Mode of Action, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Stem Cell Source, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Mode of Action, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Cancer Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Stem Cell Source, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Mode of Action, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

11. Competitive Landscape

• Lineage Cell Therapeutics, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• FUJIFILM Irvine Scientific
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Thermo Fisher Scientific Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck KGaA
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• MacroGenics, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Miltenyi Biotec
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• STEMCELL Technologies Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bionomics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sino Biological Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Celgene Corporation
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Incyte Corporation
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Lonza Group AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

12. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

13. References and Research Methodology

• References
• Research Methodology
• About us